Status:
COMPLETED
Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule
Lead Sponsor:
GlaxoSmithKline
Conditions:
Hepatitis B
Hepatitis A
Eligibility:
All Genders
7-17 years
Phase:
PHASE3
Brief Summary
The aim of this study is to evaluate the long-term persistence of hepatitis A and B antibodies at Years 6, 7, 8, 9 and 10 after subjects received their first two doses primary vaccination schedule of ...
Detailed Description
To evaluate the long-term antibody persistence, volunteers will be bled at Years 6, 7, 8, 9 and 10 after the first vaccine dose of the primary vaccination course to determine their anti-HAV and anti-H...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects participating in this study should have participated in the primary study with combined hepatitis A/ hepatitis B vaccine.
- Written informed consent will be obtained from each subject and/ or parent or guardian of the subject before the blood sampling visit of each year.
Exclusion
Key Trial Info
Start Date :
February 16 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 15 2009
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT00289744
Start Date
February 16 2004
End Date
April 15 2009
Last Update
August 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Wilrijk, Belgium, 2610